Thermo Fisher strengthens antibody services through Affymetrix merger

By Dan Stanton contact

- Last updated on GMT

Image: iStock
Image: iStock

Related tags: Biology, Dna

Thermo Fisher has expanded its life sciences tools business through the acquisition of biological analysis firm Affymetrix for $1.3bn.

The deal was originally announced in January​ but two weeks ago​ Affymetrix received a rival offer of $1.5bn from Origin Technologies Corporation.

This was rejected on the grounds that the deal was backed by an insufficient financial package, and yesterday the firms announced the acquisition has now been completed, with Affymetrix becoming a wholly-owned subsidiary of Thermo Fisher.

“This is a great outcome for both companies,”​ said Thermo Fisher CEO Marc Casper in a statement. “With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets.”

He added the integration of Affymetrix has been ongoing since the deal was announced in January. “[It is] progressing well and we look forward to creating value through the strategic and financial benefits of the transaction.”

Thermo M&A

The acquisition is the latest for Thermo Fisher as it strengthens its bioprocessing and life sciences businesses.

In 2014​, the firm bought Life Technologies for $13.6bn, adding sera and media, chromatography instruments and purification consumables to its portfolio, as well as the DNA sequencing Ion Torrent technology platform.

And last year​, the firm bolstered its single-use bioprocessing technologies offering through the acquisition of ASI.

Furthermore, the company was rumoured to have made a bid for Pall Corporation​, the filtration and separation firm which was snapped up for $14bn in September​ by Danaher.

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us


View more